This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-27 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
US forces reported killing approximately 144 individuals identified as narco-terrorists in airstrikes on suspected trafficking vessels during the Venezuelan authorities and human rights organizations disputed the US characterization, alleging many victims were civilians or fishermen. Casualties among Venezuelan military personnel and allies from related ground operations are covered in 2026 United States intervention in Venezuela.
{\displaystyle h=C{{\left[{\frac {k_{v}^{3}{{\rho }_{v}}g\left({{\rho }_{L}}-{{\rho }_{v}}\right)\left({{h}_{fg}}+0.4{{c}_{pv}}\left({{T}_{s}}-{{T}_{sat}}\right)\right)}{{{D}_{o}}{{\mu }_{v}}\left({{T}_{s}}-{{T}_{sat}}\right)}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
=== Discontinuation === The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse. In 2021, news reports described the death of a 24‑year‑old California woman, Casandra "Casi" Pastora from Chino Hills, who developed severe rebound psychosis after abruptly discontinuing risperidone and died following a confrontation with police and detention at the West Valley Detention Center in Rancho Cucamonga. Her father's attorney, Ed Lyman, stated: "I think it speaks for itself they [the San Bernardino County Sheriff's Department] knew she [Pastora] was mentally ill. They knew she was pregnant. They knew she was withdrawing from her medication and had medical needs right then and there. They could have taken her to a hospital, but they immediately detained her. In that period, she lost her baby and she lost her life."
Sources: en.wikipedia.org
BBC News reports that Paul Powlesland has become the first juror to swear an oath on a river after doing so at Snaresbrook Crown Court. New powers under the Victims and Prisoners Act come into force that prevent prisoners convicted of the most serious offences in England and Wales from marrying while in custody. One of the first uses of the new legislation is to prevent convicted murderer Levi Bellfield from entering into a civil partnership with his girlfriend. Details are published of the autumn programme of COVID-19 vaccination, which will be broadly the same as 2023 with the vaccine offered to all adults aged 65 and over, as well as certain health and social care staff, older care home residents and people in clinical risk groups. 2024 riots: Rioting breaks out in Sunderland, where protestors clash with police outside a mosque. 3 August – The BBC removes a video promoting Children in Need 2018 from its website after it emerges the video features the suspect in the 2024 Southport stabbing. 4 August – Starmer condemns the ongoing "far-right thuggery" around the UK and says those involved "will regret it", as the number of people arrested in relation to the disorder exceeds 140. At least 10 police officers are injured at the Holiday Inn Express Hotel in Rotherham, with one left unconscious after a head injury, while others have broken bones. 5 August 2024 United Kingdom riots: Starmer holds an emergency COBRA meeting of ministers, civil servants, the police and intelligence officers in response to the rioting of recent days.
=== Conservation === Arapaima are particularly vulnerable to overfishing because of their size and because they must surface periodically to breathe. Some 7000 tons per year were taken from 1918 to 1924, the height of commercial arapaima fishing; demand led to farming of the fish by native ribeirinhos. As efforts at restricting catches were largely unsuccessful, arapaima fishing was banned outright in Brazil in 1996, due to declining populations. Indeed, a 2014 study found that the fish were depleted or overexploited at 93% of the sites examined and well-managed or unfished in only 7%; the fish appeared to be extirpated in 19% of these sites. The status of the arapaima population in the Amazon River Basin is unknown, hence it is listed on the IUCN red list as data deficient. Conducting a population census in so large an area is difficult, as is monitoring catches in a trade that was once largely unregulated. Since 1999, both subsistence and commercial fishing have been permitted in specially designated areas under a sophisticated sustainable management strategy. This approach has led to massive recovery of once-depleted stocks; in a sampling of 10 areas conducted using traditional counting methods, the population was found to have grown from 2,500 in 1999 to over 170,000 in 2017. Colombia only bans fishing and consumption of the arapaima between 1 October and 15 March, during breeding season.
=== Francis Crick Graduate Lectures === The University of Cambridge Graduate School of Biological, Medical and Veterinary Sciences hosts The Francis Crick Graduate Lectures. The first two lectures were by John Gurdon and Tim Hunt.
=== Plot === Five years later, the game places the player in direct control of Major Archer, preparing for a mission aboard the Gunman space station Aeronautica. After a training level, Archer and a small detachment of Gunmen are deployed to a dinosaur-inhabited jungle planet, under orders to investigate an outdated but extremely high ranking Gunman distress signal. The signal is revealed to be a trap, and the Gunmen come under heavy attack both from unidentified human forces and the indigenous fauna. The player is eventually forced to fight his way through a series of catacombs, where he encounters the General, still alive despite having been eaten alive on Banzure Prime. He reveals to Archer that the silicon-based Xenomes are incapable of digesting carbon-based humans, and that he, the scientists from the research colony, and the other Gunmen consumed by the Xenomes managed to fight their way out of the creature's gullets after Archer left them for dead. The vengeful scientists and Gunmen have now formed a rogue cell, with the General as its leader, and are engineering new Xenome breeds to use as weapons and to exact their vengeance upon Archer. The General allows Archer to leave, so as to watch him die at the hands of the planet's vicious reptiles, but he manages to infiltrate the General's cargo ship, bound for a falling moon that plays host to an outdated AI, called the Mainframe, that has been unstable for some time since the General left it. At the moon, the ship comes under fire from the now fully insane AI's drones.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.